| From: |
|
Alison Bunce - Medicines and Healthcare Products Regulatory Agency
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
|
|
|
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Action category: |
|
Class 2: Action within 48 hours
|
| Title: |
|
DRUG ALERT CLASS 2, ACTION WITHIN 48 HOURS, MACLEODS PHARMA UK LIMITED. IRBESARTAN 150MG FILM-COATED TABLETS AND IRBESARTAN 300MG FILM-COATED TABLETS
|
| Broadcast content: |
|
Recall of affected batches due to potential contamination with N‑nitrosodiethylamine (NDEA).
Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts
|
| Cascade to: |
|
- #GP#
- #COMMUNITYPHARMACISTS#
- #DISPENSING GP#
- #HospitalPharmacy#
|